openPR Logo
Press release

GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits

02-05-2012 03:00 PM CET | Politics, Law & Society

Press release from: Nadrich & Cohen LLP

Nadrich & Cohen, LLP reports that GlaxoSmithKline has agreed to settle approximately 20,000 Avandia side effects lawsuits.

Los Angeles, CA, February 3, 2012 – UK drug-maker GlaxoSmithKline has agreed to settle 20,000 Avandia side effects lawsuits. According to a Bloomberg report, the company previously agreed to pay at least $700 million to settle more than 15,000 claims on behalf of patients who said that the drug caused heart attacks, strokes and other complications.

Avandia (rosiglitazone) was first approved by the FDA in 1999 to treat Type 2 diabetes in adult patients. The drug hit the market the same year as another popular diabetes drug, Actos (pioglitazone). The maker of Actos, Takeda Pharmaceuticals, is now facing numerous lawsuits from patients who claim the drug caused them to develop bladder cancer.

GlaxoSmithKline announced in November 2011 that it would $3 billion to the federal government in connection with claims that the company had illegally marketed Avandia. In addition to the 20,000 cases involved in the settlement agreement, Avandia side effects claims are still pending in state courts across the country. An estimated 2,500 federal lawsuits that were consolidated in a Philadelphia court have also been assigned to mediation.

Patients who experienced complications after using Avandia are encouraged to complete a MedWatch form by visiting the FDA’s website. Patients are also urged to seek the aid of an experienced personal injury lawyer to discuss their legal rights.

Nadrich & Cohen LLP is offering confidential, no-cost consultations to individuals across the country who believe they were harmed by Avandia. Help is available by calling the firm’s injury hotline at 1-800-718-4658.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Avandia side effects claims, the firm is also investigating cases involving Accutane, Actos, Zoloft, Fosamax, Paxil, Vaginal Mesh, Wright Conserve Hips, Yaz, Yasmin, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. For more information, visit

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GlaxoSmithKline Agrees to Settlement in 20,000 Avandia Lawsuits here

News-ID: 209672 • Views: 2939

More Releases from Nadrich & Cohen LLP

Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation. Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots. Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants. Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems. The two-day panel, which is expected
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country. Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the

All 5 Releases

More Releases for Avandia

Future and Growth of BRIC Diabetes Drugs Market by 2021
Diabetes drugs help in preventing complications and controlling blood glucose level in the blood. Some of the drugs used to treat type 2 diabetes are metformin, actos, avandia, lantus subcutaneous, and invokana. All drugs are administered orally except insulin, exenatide, liraglutide, and pramlintide. Insulin is delivered through insulin delivery devices including infusion pump, intravenous sets, insulin syringe, insulin pen, and jet injectors. Long acting, intermediate acting, short acting, and rapid
Pfizer Seeking Consolidation of Zoloft Birth Defects Lawsuits
Nadrich & Cohen, LLP reports that Pfizer is seeking to consolidate a number of federal Zoloft birth defects lawsuits into a multidistrict litigation. Los Angeles, CA, February 1, 2012 – Pfizer has reportedly asked a federal judicial panel to centralize a number of Zoloft birth defects lawsuits filed against the company. If the motion is granted, the cases would be consolidated for pretrial proceedings and heard in a federal district
Bristol-Meyers Squibb Sued by 72 Plaintiffs Over Plavix Side Effects
Nadrick & Cohen, LLP reports that 72 plaintiffs have joined together in a Plavix side effects lawsuit filed against Bristol-Meyers Squibb. Los Angeles, CA, January 27, 2012 – Seventy-two plaintiffs from across the country have joined together in filing a Plavix side effects lawsuit against the drug’s maker, Bristol-Meyers Squibb. According to the Madison Record, the plaintiffs are seeking an unspecified amount of compensation for injuries they say were caused
Nadrich & Cohen LLP Clarifies Statements Regarding Actos Bladder Cancer Lawsuits
Los Angeles, CA, January 24, 2012 – National law firm Nadrich & Cohen LLP would like to clarify previous statements regarding the pending Actos bladder cancer litigation. Earlier press releases included incorrect information regarding the total number of Actos lawsuits filed against the drug’s manufacturer, Takeda Pharmaceuticals. Those releases, based on media reports, estimated the number of lawsuits filed in state and federal courts nationwide in connection with Actos numbered
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings. Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the
Weitz & Luxenberg Lawyers Respond to Study Casting Further Doubt on Avandia
October 1, 2007, New York, NY— A further pall has been cast over Avandia, a drug for Type 2 diabetes. A new study has found that long-term use of the pharmaceutical increases heart attack risk by more than 40 percent and doubles the chance of heart failure. These findings are nearly identical to that of another recent scientific analysis out this spring. “Millions of people with diabetes trusted Avandia to